$MRK News Nike slips after hours as orders fail to

New Post Public Reply Private Reply Replies (0) Message Board

Dec 21, 2014 at 10:14 AM

$MRK News

Nike slips after hours as orders fail to impress 6:38 p.m. Dec. 18, 2014 - MarketWatch
Merck acquires OncoEthix for up to $375 million 8:41 a.m. Dec. 18, 2014 - Angela Chen
From China to the U.S., a surreal week in business news 9:28 a.m. Dec. 12, 2014 - Marek Fuchs
Human trial of experimental Merck Ebola vaccine is suspended 2:17 p.m. Dec. 11, 2014 - Jeanne Whalen
Restoration Hardware shares jump on earnings beat 6:46 p.m. Dec. 10, 2014 - MarketWatch
Merck drug shrank tumors in some breast cancer patients in trial 8:57 a.m. Dec. 10, 2014 - Peter Loftus
Here are today’s biggest S&P 500 losers ... and five winners 12:51 p.m. Dec. 9, 2014 - Philip van Doorn
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Sara Sjolin
Russell 2000 rattles cage on major resistance 11:15 a.m. Dec. 8, 2014 - Michael Ashbaugh
Dow 18,000 beckons, but a bottom in oil prices does not 7:42 a.m. Dec. 8, 2014 - Shawn Langlois
Newscast: Oil prices plunge 7:38 a.m. Dec. 8, 2014 - MarketWatch
Merck to buy Cubist Pharmaceuticals for $8.4 billion 7:26 a.m. Dec. 8, 2014 - Peter Loftus
Merck to buy Cubist Pharmaceuticals in $9.5 billion deal 7:13 a.m. Dec. 8, 2014 - Tomi Kilgore
Merck & Co. to buy Cubist Pharma in total deal valued at $9.5 billion 7:05 a.m. Dec. 8, 2014 - Carla Mozee
Merck's per-share bid for Cubist's stock is 37% above Friday's closing price 7:03 a.m. Dec. 8, 2014 - Tomi Kilgore
Merck & Co.: Cubist Pharma purchase is a 35% premium to shareholders 7:03 a.m. Dec. 8, 2014 - Carla Mozee
Merck to pay $102 a share for Cubist 7:02 a.m. Dec. 8, 2014 - Tomi Kilgore
Merck agrees to buy Cubist Pharmaceuticals for $9.5 bln including debt 7:02 a.m. Dec. 8, 2014 - Tomi Kilgore
Merck & Co. to buy Cubist Pharma for $102 a share in cash 7:01 a.m. Dec. 8, 2014 - Carla Mozee

Zoetis: Betting The Proverbial Farm? 8:15 a.m. Dec. 20, 2014 - Seeking Alpha
FDA Approves Cubist’s Experimental Antibiotic Zerbaxa 7:06 p.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
FDA approves Cubist's Zerbaxa 6:35 p.m. Dec. 19, 2014 - Seeking Alpha
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog 5:20 p.m. Dec. 19, 2014 - Zacks.com
FDA Approves AstraZeneca Ovarian Cancer Drug 5:12 p.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog 4:19 p.m. Dec. 19, 2014 - Zacks.com
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More 4:00 p.m. Dec. 19, 2014 - Seeking Alpha
Pharma Favorites to Stand the Trials of 2015 2:29 p.m. Dec. 19, 2014 - Barrons.com
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day 1:00 a.m. Dec. 19, 2014 - Zacks.com
U.S. Stocks Surge on Fed Reassurance 8:28 p.m. Dec. 18, 2014 - The Wall Street Journal Interactive Edition
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog 6:30 p.m. Dec. 18, 2014 - Zacks.com
Tetraphase Jumps As 'Superbug' Drug Scores In Trial 10:54 a.m. Dec. 18, 2014 - Investors Business Daily
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses 9:35 a.m. Dec. 18, 2014 - TheStreet.com
China moves ahead with Ebola vaccine trials 8:31 a.m. Dec. 18, 2014 - Seeking Alpha
Merck buys Swiss biotech firm 8:23 a.m. Dec. 18, 2014 - Seeking Alpha
Merck Acquires OncoEthix for Up to $375 Million 8:21 a.m. Dec. 18, 2014 - The Wall Street Journal Interactive Edition
Options Traders Buy the Pullback in Pharmaceuticals Giant Merck 5:45 a.m. Dec. 18, 2014 - TheStreet.com
Merck's 3.2% Yield Is The Only Reason To Own The Stock 12:53 a.m. Dec. 18, 2014 - Seeking Alpha

Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D. 8:00 a.m. Dec. 19, 2014 - BusinessWire - BZX
Merck Begins Tender Offer to Acquire Cubist 8:00 a.m. Dec. 19, 2014 - BusinessWire - BZX
Electrochromic Glass Market Will Reach $ 2.2 billion by 2020 says New NanoMarkets Report 11:14 a.m. Dec. 18, 2014 - PR Newswire - PRF
New Energy a Little More Insulated to Sharp Drop in Oil than Before 9:53 a.m. Dec. 18, 2014 - ACCESSWIRE
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform 8:02 a.m. Dec. 18, 2014 - BusinessWire - BZX
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers 7:30 a.m. Dec. 18, 2014 - BusinessWire - BZX
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors 8:31 a.m. Dec. 16, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company 7:07 p.m. Dec. 15, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information 5:07 p.m. Dec. 12, 2014 - BusinessWire - BZX
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc.in Connection With the Fairness of the Sale of the Companyto Merck & Co. 10:19 a.m. Dec. 12, 2014 - BusinessWire - BZX
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. 12:51 p.m. Dec. 10, 2014 - BusinessWire - BZX
Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health 9:30 a.m. Dec. 10, 2014 - BusinessWire - BZX
International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer 8:45 a.m. Dec. 10, 2014 - BusinessWire - BZX
Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium 8:30 a.m. Dec. 10, 2014 - BusinessWire - BZX
Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests 9:31 p.m. Dec. 9, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. -- CBST 11:49 a.m. Dec. 9, 2014 - PR Newswire - PRF
Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc. 10:53 a.m. Dec. 9, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, Merck, Alnylam Pharmaceuticals, Nu Skin Enterprises and Organovo Released By InvestorsObserver 9:31 a.m. Dec. 9, 2014 - PR Newswire - PRF
Merck Statement Regarding CUBICIN Patent Litigation 8:11 a.m. Dec. 9, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Humberto Quintanar Strengthens McKinley Irvin's Seattle Team

Humberto Quintanar Makes His Move In a world where legal battles can shake lives to the core, McKinley Irvin is throwing another heavyweight into the ring. They’ve just pulled in Humberto Quintanar, a guy who knows his way around a courtroom like a cabbie knows a city's backstreets. This isn't just another seat-fillin' lawyer; Quintanar packs years of experience as a...

Approved Oil Secures Long-Term NYC Fuel Terminal Deal

Approved Oil Locks in Future with Sunoco Deal Amidst the contraction of New York City's fuel terminal landscape, securing a consistent lifeline to crucial infrastructure feels like striking gold. Approved Oil just locked down an agreement with Sunoco for a new terminal location that'll last deep into the 2040s, and it's about more than just securing a spot on the...

Columbia Distributing Expands to Alaska: A Growth Move

Alaska's Entry: Columbia's New Frontier When Columbia Distributing dives into a new territory, you know they're serious about growth. This latest move sees them planting their flag in Alaska, finally completing a strategic vision that's been brewing for a while. Four-State Strategy Comes to Fruition The transaction with Republic National Distributing Company (RNDC) is no...

Gildan's Troubling Legal Struggles: Investor Action Alert

Gildan's Bumpy Ride: Legal Woes Unfold Well, folks, seems like Gildan Activewear Inc. (NYSE:GIL) is in for a bumpy ride, and not the kind that makes you feel alive, I tell ya. They've been slapped with a class action lawsuit, and the news ain't pretty. Accusations are flying hot about how they've been playing fast and loose with their financials. The Allegations: Channel...

DropGenie Nets $5M to Boost Functional Biology Reach

DropGenie Scores Big with Fresh Financing Boost Out of the Montreal wilderness, DropGenie is charging forward with a fresh $5 million injection in Seed+ financing. This isn't just loose change; it's a ticket to accelerating their mission of advancing functional biology platforms and beefing up data partnerships. You know, the kind of partnerships that even the suits in...

Skechers Facing Class Action: Investors Urged to Act

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Ernesta Expands Southeast Reach with Atlanta Showroom

Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...

Gildan Activewear Faces Major Class Action Lawsuit

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Bertram Capital Backs MCE's Expansive Growth Vision

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...